Pashna N. Munshi

Pashna N. Munshi

Auto-generated profile, based on publicly available information

Pashna N. Munshi

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SASairah Ahmed
Sairah Ahmed
JKJennifer A. Kanakry
Jennifer A. Kanakry
Kwang Woo AhnKwang Woo Ahn
Kwang Woo Ahn
CLCarlos Litovich
Carlos Litovich
HAHisham Abdel-Azim
Hisham Abdel-Azim
MHMehdi Hamadani
Mehdi Hamadani
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. The study included 596 adult patients who underwent a first RIC allo-HCT for cHL between 2008 and 2016 using either a haplo-PTCy (n = 139) or MSD/CNI-based (n = 457) approach. Overall survival (OS) was the primary endpoint. Secondary endpoints included acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), nonrelapse mortality (NRM), relapse/progression, and progression-free survival (PFS). On multivariate analysis, there was no significant difference between haplo/PTCy and MDS/CNI-based approaches in terms of OS (hazard ratio [HR], 1.07; 95% confidence interval [CI], .79 to 1.45; P = .66) or PFS (HR, .86; 95% CI, .68 to 1.10; P = .22). Haplo/PTCy was associated with a significantly higher risk of grades II to IV aGVHD (odds ratio [OR], 1.73, 95% CI, 1.16 to 2.59; P = .007), but the risk of grades III to IV aGVHD was not significantly different between the 2 cohorts (OR, .61; 95% CI, .29 to 1.27; P = .19). The haplo/PTCy platform provided a significant reduction in cGVHD risk (HR, .45; 95% CI, .32 to .64; P < .001), and a significant reduction in relapse risk (HR, .74; 95% CI, .56 to .97; P = .03). There was a statistically nonsignificant trend toward higher NRM with a haplo/PTCy approach (HR, 1.65; 95% CI, .99 to 2.77; P = .06). Haplo/PTCy-based approaches are associated with lower incidences of cGVHD and relapse, with PFS and OS outcomes comparable with MSD/CNI-based approaches. There was a leaning toward higher NRM with a haplo/PTCy-based platform. These data show that haplo/PTCy allo-HCT in cHL results in survival comparable with MSD/CNI-based allo-HCT.

20 August 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
PMPashna N. Munshi
Pashna N. Munshi
MHMehdi Hamadani
Mehdi Hamadani
AKAmbuj Kumar
Ambuj Kumar
PDPeter Dreger
Peter Dreger
JFJonathan W. Friedberg
Jonathan W. Friedberg
TFTimothy S. Fenske
Timothy S. Fenske

20 November 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
SNSattva S. Neelapu
Sattva S. Neelapu
JCJulio C. Chavez
Julio C. Chavez
ASAlison R. Sehgal
Alison R. Sehgal
Narendranath EpperlaNarendranath Epperla
Narendranath Epperla
MUMatthew L. Ulrickson
Matthew L. Ulrickson
CJCaron A. Jacobson
Caron A. Jacobson
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrolled patients with R/R indolent non-Hodgkin lymphoma (iNHL; 127 with FL and 31 with marginal zone lymphoma) after a median follow-up of 64.6 months. Patients underwent leukapheresis and received lymphodepleting chemotherapy and axi-cel (2 × 10 6 CAR T cells/kg). The overall response rate was 90% (75% complete response rate). The median duration of response was 60.4 months, and the median progression-free survival (PFS) was 62.2 months; median time to next treatment and overall survival were not reached (NR). At data cutoff, 55% of patients were alive without requiring subsequent anticancer therapy. Median lymphoma-specific PFS in patients with FL was NR; 34% had progression or death due to lymphoma or study treatment. Notably, after 30 months postinfusion, progression or lymphoma-related deaths were rare. Late-onset toxicities were infrequent and largely unrelated to axi-cel. Durable response and prolonged survival in FL were associated with robust early CAR T-cell expansion and naïve product phenotype. These findings confirm sustained responses and manageable safety with axi-cel in the long term among patients with R/R iNHL and its potential as a curative therapy in FL.

31 October 2023 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
CUCelalettin Ustun
Celalettin Ustun
MCMin Chen
Min Chen
SKSoyoung Kim
Soyoung Kim
JAJeffery J. Auletta
Jeffery J. Auletta
MBMarjorie V. Batista
Marjorie V. Batista
GPGenovefa A. Papanicolaou
Genovefa A. Papanicolaou

23 January 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
Hemant MurthyHemant Murthy
Hemant Murthy
Kwang Woo AhnKwang Woo Ahn
Kwang Woo Ahn
NENoel Estrada-Merly
Noel Estrada-Merly
HAHassan B. Alkhateeb
Hassan B. Alkhateeb
SBSusan Bal
Susan Bal
WSWael Saber
Wael Saber
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy with limited treatment options and poor long-term survival. Previous studies of allogeneic hematopoietic cell transplantation (alloHCT) for T-PLL are limited by small numbers, and descriptions of patient and transplant characteristics and outcomes after alloHCT are sparse. To describe outcomes of alloHCT in T-PLL and identify predictors of post-transplant relapse and survival. We conducted an analysis of data using the Center for International Blood and Marrow Transplant Research (CIBMTR) database on 266 patients with T-PLL who underwent alloHCT during 2008–2018. The 4-year rates of overall survival (OS), disease-free survival (DFS), relapse, and treatment-related mortality (TRM) were 30.0% (95% CI, 23.8–36.5%), 25.7% (95% CI, 20–32%), 41.9% (95% CI, 35.5–48.4%), and 32.4% (95% CI, 26.4–38.6%), respectively. In multivariable analyses, three variables were associated with inferior OS: myeloablative conditioning (MAC) (hazard ratio [HR] 2.18, p<0.0001); age older than 60 years (HR 1.61, p=0.0053); and suboptimal performance status defined by Karnofsky Performance Status (KPS) <90 (HR 1.53, p=0.0073). MAC also was associated with increased TRM (HR 3.31, p<0.0001), increased cumulative incidence of grade 2–4 acute graft-versus-host disease (GVHD) (HR 2.94, p=0.0011) and an inferior disease-free survival (HR 1.86, p=0.0004). Conditioning intensity was not associated with relapse; however stable disease/progression correlated with increased risk of relapse (HR 2.13, p=0.0072). Both in vivo T cell depletion (TCD) as part of conditioning and KPS <90 were associated with worse TRM and inferior DFS. Total Body Irradiation was not found to have any significant effect on OS, DFS or TRM. Our data showed that reduced-intensity conditioning without in vivo T-cell depletion (that is, without ATG or alemtuzumab) prior to alloHCT was associated with long-term disease-free survival in patients with T-PLL who were 60 or younger or who had KPS >90 or had chemo-sensitive disease.

10 August 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
PMPashna N. Munshi
Pashna N. Munshi
DVDavid H. Vesole
David H. Vesole
AMAndrew St. Martin
Andrew St. Martin
ODOmar Davila
Omar Davila
SKShaji Kumar
Shaji Kumar
ADAnita D’sOuza
Anita D’sOuza